Evidence map›Paper›PMID 41974450›Full record

ArticleEuropean journal of haematology2026

Low Risk of Central Nervous System Relapse Among Patients With T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Despite High-Risk Disease Presentation.

Atte Karhu, Sara Aronen, Aino Rönkä, Kaisa Sunela, Tuula Klaavuniemi, Annikki Aromaa-Häyhä, Milla Kuusisto, Otto Jokelainen, Jan Böhm, Kristiina Vuolukka and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Atte KarhuFaculty of Medicine, University of Oulu, Oulu, Finland.ORCID https://orcid.org/0009-0001-2609-2068
Sara AronenFaculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Aino RönkäDepartment of Oncology, Kuopio University Hospital, Kuopio, Finland.
Kaisa SunelaFinnish Medicines Agency (FIMEA), Helsinki, Finland.
Tuula KlaavuniemiFaculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Annikki Aromaa-HäyhäDepartment of Oncology, Kuopio University Hospital, Kuopio, Finland.
Milla KuusistoDepartment of Haematology, Oulu University Hospital, Oulu, Finland.ORCID https://orcid.org/0000-0002-4435-4199
Otto JokelainenFaculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.ORCID https://orcid.org/0000-0002-9166-531X
Jan BöhmDepartment of Pathology, Hospital Nova, Jyväskylä, Finland.
Kristiina VuolukkaFaculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Ulla-Mari ArkkoDepartment of Oncology and Radiotherapy, North Carelia Central Hospital, Joensuu, Finland.
Samuli VaittinenDepartment of Pathology, Turku University Hospital, Turku, Finland.
Minna HarmanenFaculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.ORCID https://orcid.org/0000-0001-8799-9985
Juha P VäyrynenTranslational Medicine Research Unit, University of Oulu and Oulu University Hospital, Oulu, Finland.ORCID https://orcid.org/0000-0002-8683-2996
Hanne KuitunenDepartment of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.
Sonja NousiainenFaculty of Medicine, Tampere University, Tampere, Finland.
Joonas KuitunenFaculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.ORCID https://orcid.org/0009-0009-9790-2863
Juho KangasFaculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Eetu PellonperäFaculty of Medicine, University of Oulu, Oulu, Finland.ORCID https://orcid.org/0009-0001-5380-2598
Henri KurttilaFaculty of Medicine, University of Oulu, Oulu, Finland.
Miko PietiläFaculty of Medicine, University of Oulu, Oulu, Finland.
Jaakko TirkkonenFaculty of Medicine, University of Oulu, Oulu, Finland.
Outi KuittinenFaculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.ORCID https://orcid.org/0000-0001-9969-0053

Funding

Incyte
6 · The paper itself

Abstract

T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare subtype of large B-cell lymphoma (LBCL) for which central nervous system (CNS) relapse remains a devastating complication. The CNS International Prognostic Index (IPI) is usually used to predict the risk of CNS relapse. However, the overall risk of CNS relapse among patients with THRLBCL remains poorly known. To clarify the risk of CNS relapse in THRLBCL, data for 106 patients with THRLBCL diagnosed between 2000 and 2020 were collected from seven hospitals throughout Finland. The control data consisted of 660 patients with diffuse LBCL (DLBCL) diagnosed and treated in Oulu University Hospital. Most of the patients with THRLBCL and DLBCL presented with advanced stage disease and were classified as high-intermediate or high-risk groups based on their IPI score. 368 patients received R-CHOP as first line therapy. Our data included patients who had received CNS prophylaxis. For the entire patient population, we found a 5-year CNS relapse risk of 1.04% and 5.29% among patients with THRLBCL and DLBCL, respectively (p < 0.001). In conclusion, THRLBCL has lowered CNS relapse risk compared to DLBCL.

Indexed as

Central Nervous System NeoplasmsHistiocytesLymphoma, Large B-Cell, DiffuseT-LymphocytesAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDoxorubicinFemaleFinlandHumansMaleMiddle AgedNeoplasm StagingPrognosisDoxorubicinCNS prophylaxisCNS relapselarge B‐cell lymphomaTHRLBCL

Identifiers

PMID41974450
PMCPMC13326783

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.